CN Patent

CN112353762A — 具有改善的生物利用度的药物组合物

Assigned to F Hoffmann La Roche AG · Expires 2021-02-12 · 5y expired

What this patent protects

本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4‑{[(2R,3S,4R,5S)‑4‑(4‑氯‑2‑氟苯基)‑3‑(3‑氯‑2‑氟苯基)‑4‑氰基‑5‑(2,2‑二甲基丙基)‑吡咯烷‑2‑羰基]氨基}‑3‑甲氧基‑苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。

USPTO Abstract

本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4‑{[(2R,3S,4R,5S)‑4‑(4‑氯‑2‑氟苯基)‑3‑(3‑氯‑2‑氟苯基)‑4‑氰基‑5‑(2,2‑二甲基丙基)‑吡咯烷‑2‑羰基]氨基}‑3‑甲氧基‑苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。

Drugs covered by this patent

Patent Metadata

Patent number
CN112353762A
Jurisdiction
CN
Classification
—
Expires
2021-02-12
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.